BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?
2026-09-03 21:30
•Prosper Junior Bakiny •The Motley Fool
••• ••••• Axe Cap view
Moderna Leads the Race in Cancer Vaccine Innovation
Moderna’s recent clinical successes give it the edge over BioNTech in the evolving cancer vaccine market.
After mRNA vaccines took centre stage during the pandemic, both Moderna and BioNTech are pivoting toward cancer vaccines. Moderna’s recent phase 3 trial wins for its personalized cancer vaccine, intismeran autogene, and FDA approval of its mFLUSIVA flu vaccine, signal stronger near-term commercial prospects. BioNTech still has a solid pipeline, including pumitamig, but lacks the late-stage clinical proof Moderna now sports. Globally, this underpins Moderna’s premium valuation at around $61 billion versus BioNTech’s $26 billion. Locally, direct exposure is limited since neither firm is JSE-listed. However, rand volatility against the USD (USD/ZAR) might be a factor if you consider offshore mRNA plays. Within the JSE, it’s best to watch sectors linked indirectly to biotech innovation or global pharma collaborations, such as Sanlam or even Naspers through Prosus’s tech investments. Take care though—clinical development is inherently binary. One failed trial or regulatory delay could swiftly cut the hype and valuations. this is just our opinion and not financial advice
Given current data, tilt your offshore biopharma exposure toward Moderna, while using USD/ZAR as a barometer for timing purchases. Stay cautious on BioNTech until phase 3 results solidify. Locally, hold or selectively watch innovation-linked counters but avoid direct biotech bets.
- MRNA
- USD/ZAR
- Naspers
- trial failures disrupt valuations
- rand weakness inflates offshore investment costs
6/10
BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.
Our take is based on reporting first published by The Motley Fool.
More stories like this
- Intapp Chief Product Officer Thad Jampol Sells 25,000 Shares
- Tim Cook Grew Apple From a $350 Billion Company Into a Multi-Trillion-Dollar Giant Over Nearly 15 Years as CEO. Can John Ternus' Product-First Approach Extend That Compounding?
- With Nearly 40% Short Interest, Is SoundHound Stock a Buy or Sell?